Dr. Garassino on the PACIFIC Trial for NSCLC

Marina Chiara Garassino, MD
Published: Tuesday, Sep 19, 2017



Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the PACIFIC study for patients with non–small cell lung cancer (NSCLC).

PACIFIC is a randomized, phase III clinical trial investigating durvalumab (Imfinzi) versus placebo after a period of chemoradiotherapy in stage III NSCLC. There was a lack of new therapies for patients in this population, states Garassino.

The results suggest that there is an increase of progression-free survival of 10 months, explains Garassino. Results on the overall survival are not yet known. In the future, durvalumab has the potential to be the standard of care.
 


Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the PACIFIC study for patients with non–small cell lung cancer (NSCLC).

PACIFIC is a randomized, phase III clinical trial investigating durvalumab (Imfinzi) versus placebo after a period of chemoradiotherapy in stage III NSCLC. There was a lack of new therapies for patients in this population, states Garassino.

The results suggest that there is an increase of progression-free survival of 10 months, explains Garassino. Results on the overall survival are not yet known. In the future, durvalumab has the potential to be the standard of care.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x